1[1]Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials[J]. Lancet. 1998,351(9114):1451-1467.
2[2]NSABP halts B-14 trial: No benefit seen beyond 5 years of tamoxifen use[J]. J Natl Cancer Inst. 1995,87(24):1829.
3[3]Jukkola A, Bloigu R, Soini Y, et al.c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor re sponse to hormonal or chemotherapy treatment in advanced disease[J]. Eur J Cancer. 2001,37(3):347-354.
4[4]Baum M, Budzar AU, Cuziek J, et al. ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post menopausal women with early breast cancer: first results of the ATAC randomised trial [J]. Lancet. 2002,359(9324):2131-2139.
5[5]On behalf of the ATAC irialists'Group. The ATAC ('Arimidex', Tamexifer, Alone or in combination) trial in post menopausal women with early breast cancer-Updated effi cacy results based on a maiden follow-up of 47 months. The Breast 12(suppl 1), 2003,S47.
6[6]A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer[J]. N Engl J Med. 2003,349(19):1793-1802.
7[7]Schumacher M, Biamey R, Cuzick J, et al. Updated survival analyses from the ZEBRA study: goserelin vs CMF in premenopausal women with node-positive breast cancer. The Breast 12(suppl 1), 2003,S37.
2Segaloff AT. Hormon treatment of breast cancer. Amer Med Assol, 1997;234:1175.
3Van Leeuwon FE. Risk of endometral Cancer after tamoxifen treatment of Breast Cancer. Lancet, 1994;343(8895):448.
4Jain J, Samaal B, Sighakowinta A, et al. Clinical trial of Nafoxidine in adrenalectomy patienys with advanced breast cancer. Cancer, 1997;40:2063.
5Lamb HM, Adkins JC. Letrozole-a reviews of its use in postmenopausal Women With advanced breast cancer [J]. Drugs, 1998;56(6):1125.
6Jordan VC, Tamoxifen: a most unlikely pioneering medicine [J]. Nat Rev Drug Discov, 2003;2(3):205～213.
7Piccart M, Parker LM, Pritchard KI. Oestrogen receptor downregulation; an opportunity for extending the window of endocrine therapy in advanced breast cancer [J]. Ann Oncoi, 2003;14(7):1017～1025.
8Shannon C, Smith I. Is there still a role for neoadjuvant therapy in breast [J]. Crit Rev Oncol He matol, 2003;45(1):77～90.
9Smith IE, Dowett M. Aromatase inhibitors in breast cancer. N EngI J Med, 2003;348:2431～2442.
10Parnes HL, Cirrincione C, Aisner J, et al. Phase Ⅲ study of cyclophosphamide, doxorubicin,and fluorouracil (CAF)plus leucovorin versus CAF for metastatic breast cancer:Cancer and Leukemia Group B9140[J]. J Clin Oncol, 2003,21(9):1819-1824.
